M13 Major Coat Protein Inhibitors
The M13 major coat protein, often referred to simply as the major coat protein (MCP), is a crucial component of the filamentous bacteriophage M13, a virus that infects Escherichia coli bacteria. The primary function of the M13 MCP is to form the structural framework of the viral capsid, providing stability and protection to the viral genome during infection. The capsid consists of thousands of copies of the MCP arranged in a helical fashion, enclosing the single-stranded DNA genome of the virus. Additionally, the MCP plays a pivotal role in the assembly and maturation of the viral particles, ensuring the efficient production and release of infectious virions from the host bacterial cell.
Inhibition of the M13 major coat protein can occur through various mechanisms, ultimately leading to the disruption of viral capsid formation and impairing viral replication. One common approach to inhibiting the MCP involves targeting its structural integrity through the disruption of protein-protein interactions essential for capsid assembly. Small molecules or peptides that specifically bind to critical regions of the MCP, inhibiting proper oligomerization and assembly, can effectively inhibit viral replication. Additionally, inhibition of host factors or cellular machinery required for MCP synthesis and capsid formation can hinder viral propagation. For instance, targeting host chaperones or enzymes involved in protein folding and post-translational modification processes necessary for MCP maturation can impede viral assembly. Furthermore, interference with viral genome packaging or capsid stability through the disruption of nucleic acid-protein interactions can serve as an effective strategy for inhibiting M13 virion formation. Overall, inhibition of the M13 major coat protein represents an antiviral approach by targeting crucial steps in viral replication and assembly, thereby curbing the spread of M13 bacteriophage.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $149.00 $210.00 $714.00 $2550.00 $10750.00 $21410.00 $40290.00 | 5 | |
Suramin inhibits the M13 Major Coat Protein indirectly by blocking purinergic receptor signaling. It antagonizes P2X and P2Y receptors, disrupting ATP-mediated signaling pathways, which are essential for the activation and function of the M13 protein. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3-kinase, a crucial component of the PI3K/AKT signaling pathway. By blocking this pathway, Wortmannin indirectly suppresses M13 Major Coat Protein, which is downstream of PI3K/AKT. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine inhibits multiple protein kinases, including those involved in MAPK signaling. This broad kinase inhibition indirectly modulates M13 Major Coat Protein by disrupting the intricate cross-talk between MAPK pathways and M13. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a selective inhibitor of p38 MAPK, a key player in stress response signaling. Inhibiting p38 MAPK indirectly influences M13 Major Coat Protein, as p38 MAPK can regulate pathways that intersect with M13-related processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3-kinase, impacting the PI3K/AKT pathway. Through this inhibition, LY294002 indirectly modulates M13 Major Coat Protein, as it interferes with the upstream signaling events crucial for M13 activation and function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of MEK1, impacting the MAPK/ERK pathway. Its inhibition of MEK1 indirectly modulates M13 Major Coat Protein, as the MAPK/ERK pathway regulates cellular events that intersect with M13-related processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, a component of the MAPK pathway. Its inhibition indirectly influences M13 Major Coat Protein, as the JNK pathway interacts with processes crucial for M13 activation and function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a central regulator of cellular growth and proliferation. By inhibiting mTOR, Rapamycin indirectly modulates M13 Major Coat Protein, as mTOR signaling intersects with processes relevant to M13 protein regulation. | ||||||
LY 303511 | 154447-38-8 | sc-202215 sc-202215A | 1 mg 5 mg | $66.00 $273.00 | 3 | |
LY303511 is a selective inhibitor of PDK1, a kinase upstream of AKT in the PI3K/AKT pathway. By inhibiting PDK1, LY303511 indirectly influences M13 Major Coat Protein, as it disrupts the signaling cascade crucial for M13 activation and function. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $260.00 | ||
LY3214996 inhibits ERK, a key player in the MAPK/ERK pathway. Its inhibition indirectly modulates M13 Major Coat Protein, as ERK regulates cellular events that intersect with processes relevant to M13-related functions. | ||||||